Conditions: Glaucoma, Open-Angle Ocular Hypertension
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 31
Healthy volunteers: no

Brief summary:
This study will characterize the effect of PF-04217329, alone and in combination with latanoprost, on circadian intraocular pressure and blood pressure in glaucoma patients. Blood samples will be collected to measure the amount of active metabolite of PF-04217329 in the plasma following dosing.

Detailed description:

Arms:
arm 1: Active study drug + latanoprost vehicle arm 2: Active study drug + latanoprost

Interventions: intervention 1: PF-04217329 intervention 2: latanoprost vehicle intervention 3: PF-04217329 intervention 4: latanoprost
Intervention descriptions: intervention 1: Topical ocular solution, once-daily for 14 days intervention 2: Topical ocular solution, once-daily for 14 days intervention 3: Topical ocular solution, once-daily for 14 days intervention 4: Topical ocular solution, once-daily for 14 days

Protocol document: